June 28, 2017 7:42am

 

As the sector will trickle with some ups and downs

 

As the IBB is down -0.03%, the XBI -0.05%, the XLV is not indicating as the IWM is up +0.33%

 

Safety is sitting on the sidelines

 

Pre-open indication:  four (4), 2 BUY and 2 SELLS

 

A critical indication ahead of “our” universe’s open!

 

Are you a subscriber?  If not – you’re missing the realities of “our” universe! 

 

 

I know what a company is supposed to look like, be like, and smell like to succeed!

 

Mixed opening expected

 

Dow futures are UP +0.05% and NASDAQ futures are DOWN -0.38%

 

 

U.S. stock index futures pointed to a mixed to slightly higher opening on Wednesday, as investors turned their attention to upcoming data releases, while keeping a watchful eye on moves in the tech and oil space.

European markets were lower during mid-morning trade, as technology stocks slumped after weakness seen on Wall Street in the previous session.

Asian indexes closed mostly lower after a softer lead from yesterday’s market, with the vote on a bill to replace Obamacare in the U.S. delayed.

 

Data docket: mortgage applications are due out at 7.00 a.m. ET, followed by international trade in goods at 8.30 a.m. ET, and pending home sales at 10.00 a.m. ET.

 

 

The cell therapy sector closed POSITIVE on Monday, Friday, Thursday and Wednesday and NEGATIVE last Tuesday.

The cell therapy sector’s record over the last 5 sessions (of 43 covered companies):

·         Tuesday closed NEGATIVE with 32 decliners, 10 advancers and 1 flat;

·         Monday closed POSITIVE with 15 decliners, 26 advancers and 2 flats;

·         Friday closed POSITIVE with 14 decliners, 24 advancers and 5 flats;

·         Thursday closed POSITIVE with 12 decliners, 27 advancers and 4 flats

·         Last Wednesday closed POSITIVE with 13 decliners, 27 advancers and 3 flats;

 

 

Remembering Tuesday’s closing bell newsletter, “another I told you so … As I had stated, “the slippage begins as the old battle of the overbought heated up as the oversold simmered.”

Reiterating, “Short-term volatility as momentum ebbs and flows over the past few days, but the impact to the cell therapy sector has been minimal until … today.  Sector stocks plunge as the market rolls over while some of past week’s appreciator’s: BLUE, JUNO, KITE, RGNX and SGMO are slipping.”

As I had stated last week, “ENJOY the high, this week will be the determinant as the month and quarter ends and many traders retreat for the July 4th week … EARLY!”

 

​Headed to a holiday and early travel time - cut your longs and shorts and regroup ...

 

 

What did I see on Tuesday, the DOW closed DOWN -0.46% (-98.20) as the NASDAQ closed DOWN -1.61% (-100.53) with the CBOE Volatility Index (VIX) widely considered the best gauge of fear in the market, above 11.07 … up +11.72% following Monday traded near 9.7, breaking below 10 for the first time since June 9,

 

 

You’ve made it to the office, turned on the monitor, having just gotten your coffee and it hits you - what could be today’s trades? 

Watch list:

  • The iShares Nasdaq Biotechnology (IBB) closed down -2.76% on Tuesday, the aftermarket indicated a negative -0.19% and indicated a negative -0.03% in Wednesday’s pre-market;
  • The SPDR S&P Biotech ETF (XBI) closed Tuesday -3.53%, the aftermarket indication was a negative -0.27% and is indicating a NEGATIVE -0.05% In Wednesday’s pre-market;
  • The Health Care Select Sector SPDR ETF (XLV) closed down -0.91% Tuesday, the aftermarket indication was a negative -0.08% and is NOT indicating in Wednesday’s pre-open;
  • The iShares Russell 2000 (IWM) closed down -0.88% on Tuesday, the aftermarket indication was a positive +0.02% and indicating a POSITIVE +0.33% in Wednesday’s pre-open

 

 

Companies in my headlights:

………. We are about to define complacency in the sector …….

Biostage (BSTG) closed up +$0.038 to $0.378 following Monday’s $0.34 (+$0.03)following Friday’s $0.31, Thursday’s $0.36, Wednesday’s $0.31 and last Tuesday’s $0.30. It’s a purely day trader play, who else would invest with the current terminal death suit hanging over BSTG’s head.  Another 9.7 M shares prices at $0.315 and 9.7 M warrants – there is already TOO much warrants liability out there. The newest offering , not to happen until August 15 is TOO full of holes and might have a problem with the SEC as to shareholder rights which have to be altered. Still a day trading PLAY – Maintaining SELL;

bluebird bio (BLUE) closed down -$4.20 to $106.90 after Monday’s $111.10 (-$0.90) following Friday’s $112.00 (-$6.50) after Thursday’s $118.50 (-$1.80) following Wednesday’s $120.30 (+$7.30). June started at $79.20; saw a high of $120.30 and a low of $79.20. The aftermarket indication is a positive +$0.40 or +0.37% - SELL on offering and BUY on capitalization;

Histogenics (HSGX) closed down -$0.05 to $1.80. HSGX’s P3 Clinical Trial of NeoCart® enrollment completed to treat knee Cartilage damage. HSGX is also on track for top-line 1 year powered data and potential BLA filing in Q3/18 with a potential BLA to the FDA shortly thereafter and, if approved, launching NeoCart in the second half of 2019 - BUY

Osiris (OSIR) closed up +$0.13 to $6.32 after Friday’s $6.18 (+$0.29). June started at $6.05; saw a high of $6.19 and a low of $5.60 which was seen twice in the month. A new CEO’s announcement helps the pricing but, doesn’t lighten the load of its legal issues – Maintaining SELL; 

 

 

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

Henry’s comments are for informational purposes only and are not a substitute for personalized advice. Consult your advisor about what is best for you.